Search research articles
Contact Us
Filters
Showing results (1-10 of 30) with videos related to
Page
of 3
Sort By:
Immunity
|
January 21, 2014
Th17 cells at the crossroads of autoimmunity, inflammation, and atherosclerosis
Nicholas van Bruggen, Wenjun Ouyang
Nature Reviews. Drug Discovery
|
July 2, 2008
Molecular imaging in drug development
Jürgen K Willmann, Nicholas van Bruggen, Ludger M Dinkelborg, et al.
Current Atherosclerosis Reports
|
May 3, 2013
Anti-inflammatory strategies for plaque stabilization after acute coronary syndromes
Amos Baruch, Nicholas van Bruggen, Juyong Brian Kim, et al.
Drug Discovery Today. Technologies
|
July 4, 2014
New imaging paradigms in drug development: the PET imaging approach
Jan Marik, Sandra M Sanabria Bohorquez, Simon-Peter Williams, et al.
Magnetic Resonance in Medicine
|
July 29, 2010
Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab
Ruediger E Port, Lisa J Bernstein, Daniel P Barboriak, et al.
Plos One
|
July 23, 2013
Inhibition of VEGF-C modulates distal lymphatic remodeling and secondary metastasis
Alvin Gogineni, Maresa Caunt, Ailey Crow, et al.
The Journal of Biological Chemistry
|
May 18, 2004
A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response
Dhaya Seshasayee, Hua Wang, Wyne P Lee, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
September 30, 2008
Reactive hyperemia and BOLD MRI demonstrate that VEGF inhibition, age, and atherosclerosis adversely affect functional recovery in a murine model of peripheral artery disease
Joan M Greve, Simon P Williams, Lisa J Bernstein, et al.
Magnetic Resonance in Medicine
|
March 9, 2004
Quantification of tumor tissue populations by multispectral analysis
Richard A D Carano, Adrienne L Ross, Jed Ross, et al.
EJNMMI Research
|
June 2, 2012
FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973
Andreas R Baudy, Taner Dogan, Judith E Flores-Mercado, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 30) with videos related to
Sort By:
Page
of 3
Immunity
|
January 21, 2014
Th17 cells at the crossroads of autoimmunity, inflammation, and atherosclerosis
Nicholas van Bruggen, Wenjun Ouyang
Nature Reviews. Drug Discovery
|
July 2, 2008
Molecular imaging in drug development
Jürgen K Willmann, Nicholas van Bruggen, Ludger M Dinkelborg, et al.
Current Atherosclerosis Reports
|
May 3, 2013
Anti-inflammatory strategies for plaque stabilization after acute coronary syndromes
Amos Baruch, Nicholas van Bruggen, Juyong Brian Kim, et al.
Drug Discovery Today. Technologies
|
July 4, 2014
New imaging paradigms in drug development: the PET imaging approach
Jan Marik, Sandra M Sanabria Bohorquez, Simon-Peter Williams, et al.
Magnetic Resonance in Medicine
|
July 29, 2010
Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab
Ruediger E Port, Lisa J Bernstein, Daniel P Barboriak, et al.
Plos One
|
July 23, 2013
Inhibition of VEGF-C modulates distal lymphatic remodeling and secondary metastasis
Alvin Gogineni, Maresa Caunt, Ailey Crow, et al.
The Journal of Biological Chemistry
|
May 18, 2004
A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response
Dhaya Seshasayee, Hua Wang, Wyne P Lee, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
September 30, 2008
Reactive hyperemia and BOLD MRI demonstrate that VEGF inhibition, age, and atherosclerosis adversely affect functional recovery in a murine model of peripheral artery disease
Joan M Greve, Simon P Williams, Lisa J Bernstein, et al.
Magnetic Resonance in Medicine
|
March 9, 2004
Quantification of tumor tissue populations by multispectral analysis
Richard A D Carano, Adrienne L Ross, Jed Ross, et al.
EJNMMI Research
|
June 2, 2012
FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973
Andreas R Baudy, Taner Dogan, Judith E Flores-Mercado, et al.
Page
of 3